NR565 / NR 565 Advanced Pharmacology Fundamentals Exam Week 1 Review . Chamberlain College of Nursing

Document Content and Description Below

NR-565 Advanced Pharmacology Fundamentals Week 1 Exam Review 1. Genetic polymorphisms (drug polymorphisms) Effect the pharmacokinetics of specific drugs or drug classes due to: - varying... expression of the particular CYP 450 enzyme family that metabolizes the drug - may affect a drug target (receptor) - we can now test for some of these variants seen among cultures 2. Genetic polymorphisms interact with: - 3. Warfarin resistance may be seen in patients with VCORC1 mutation, leading to: - 4. Genetic testing for VCORC1 mutation to assess potential warfarin resistance is required prior to prescribing warfarin. - 5. Inhibition of P-glycoprotein by a drug such as quinidine may lead to: - 6. Pharmacogenetic testing is required by the U.S. Food and Drug Administration prior to prescribing: - 7. Drug Development Process - 8. Preclinical stage of R&D - 9. Clinical Stage - 10. Drug Discovery - 11. Graded dose response - 12. Types of Drug Response - 13. Receptors exist in what two states? - 14. Four major receptor families- receptors are proteins that transduce extracellular signals to intracellular responses - 15. Ion Channel Receptors / Gated ion channels - 16. G protein-coupled receptors (Guanine nucleotide regulatory proteins) - 17. Transmembrane receptors - 18. Intracellular receptors - 19. Intracellular receptors are different receptors in what way? - 20. Enzymes - 21. Six ways gene expression can be regulated between DNA + protein - 22. Drug action at receptors - 23. agonists - 24. Antagonists - 25. partial agonists - 26. Pharmacokinetics - 27. Pharmacodynamics - 28. Absorption - 29. Distribution - 30. Metabolism - 31. First Pass Effect (Metabolism) Non-synthetic - 32. Phase I Reactions - 33. Phase II reactions - 34. CYP 450 and Drug Metabolism - 35. CYP3A4 - 36. Drug Metabolizing Enzymes - 37. Elimination - 38. Drug interactions - 39. Always consider drug-drug interactions with: - 40. CYP 2D6 - 41. A provider may consider testing for CYP2D6 variants prior to starting tamoxifen for breast cancer to: - 42. Grapefruit juice contains furanocoumarins that have been found to: - 43. Polymorphisms:2D6 - 44. poor metabolizers - 45. intermediate metabolizers - 46. Extensive metabolizers - 47. ultrarapid metabolisms (UEMs) - 48. Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to: - 49. Cytochrome P450 Enzymes - - 50. Top 10 CYP450 Drugs - 51. health disparities in the US: Barriers to adequate health care For the culturally diverse in the U.S. patient population, can occur because of: - 52. Cultural considerations in pharmacology - 53. Cultural considerations in the nursing process - 54. Cultural assessment - 55. Ethno-pharmacology - 56. African Americans - 57. Puerto Ricans - 58. Mexicans - 59. Hispanics/Latinos - 60. Asians and Hispanics - [Show More]

Last updated: 1 month ago

Preview 1 out of 16 pages